

Claims

1. An anti-CD38 antibody or antibody fragment for use in the treatment of an immune complex-mediated disease in a subject.
- ~~1.2.~~ Use of an anti-CD38 antibody or antibody fragment in the treatment of an immune complex-mediated disease.
- ~~2.3.~~ An anti-CD38 antibody or antibody fragment for use according to claim 1, wherein the immune complex - mediated disease is a kidney disease.
- ~~3.4.~~ An anti-CD38 antibody or antibody fragment for use according to claim ~~32~~, wherein the immune complex - mediated disease is selected from IgA nephropathy, lupus nephritis, Henoch-Schönlein purpura nephritis, post-streptococcal glomerulonephritis or drug-induced immune complex - mediated diffuse proliferative glomerulonephritis.
- ~~4.5.~~ An anti-CD38 antibody or antibody fragment for use according to claim ~~43~~, wherein the IgA nephropathy is a galactose-deficient IgA1 antibody (Gd-IgA1) and anti-galactose-deficient IgA1 antibody (anti-GD-IgA1) positive IgA nephropathy.
- ~~5.6.~~ An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the antibody comprises a HCDR1 region of amino acid sequence SEQ ID NO.: 1, a HCDR2 region of amino acid sequence SEQ ID NO.: 2, a HCDR3 region of amino acid sequence SEQ ID NO.: 3, and a LCDR1 region of amino acid sequence SEQ ID NO.: 4, a LCDR2 region of amino acid sequence SEQ ID NO.: 5 and a LCDR3 region of amino acid sequence SEQ ID NO.: 6.
- ~~6.7.~~ An anti-CD38 antibody or antibody fragment for use according to claim ~~65~~, wherein anti-CD38 said antibody or antibody fragment comprises a variable heavy chain (VH) region of SEQ ID NO.: 7 and a variable light chain (VL) region of SEQ ID NO.: 8.

~~7.8.~~ An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein said antibody or antibody fragment specific for CD38 is an IgG1.

~~8.9.~~ An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein said antibody or antibody fragment specific for CD38 is a human antibody.

~~9.10.~~ An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the antibody depletes plasma cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP).

~~10.11.~~ An anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein administration of said anti-CD38 antibody or antibody fragment leads to a reduction of immune complexes.

~~11.12.~~ An anti-CD38 antibody or antibody fragment for use according to any one of claims ~~54~~ to ~~1140~~, wherein the immune complex comprises Gd-IgA1 and anti-GD-IgA1 antibodies.

~~12.13.~~ An anti-CD38 antibody or antibody fragment for use according to claim ~~1140~~ or ~~1244~~, wherein the immune complex is deposited in the glomeruli of the kidney.

~~13.14.~~ The anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the antibody or antibody fragment will be dosed depending on subject body weight.

~~14.15.~~ The anti-CD38 antibody or antibody fragment for use according to claim ~~1443~~, wherein the antibody or antibody fragment will be dosed in at least 2 doses, at least 5 doses, or at least 9 doses according to Table 6.

~~15.16.~~ The anti-CD38 antibody or antibody fragment for use according to any of the preceding claims, wherein the subject to be treated is characterized by proteinuria at screening of ≥ 1.0 g/day.